Clinical Trial Update: Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib [Phase 2]

View source ↗

Summary

Phase 2 trial investigating molecular response in adult Ph+ CML patients in chronic phase treated with nilotinib after suboptimal response to imatinib; study te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia Chronic Phase

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Status: TERMINATED | Results posted: 2021-08-18